Citations 2
The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI): Overview of consortium sites and anticipated enrollment
Oomens, Julie Elisabeth , Biber, Sarah , Albert, Marilyn, Alosco, Michael L. , Arfanakis, Konstantinos , Brewer, James B., Chin, Erin, Clark, Lindsay R. , Cohen, Ann D. , Dage, Jeffrey L. , Detre, John A. , DiFilippo, Frank P. , Dyck, Christopher H. van , Grabowski, Thomas J. , Habes, Mohamad, Hedden, Trey , Jagust, William, Jefferson, Angela L. , Kecskemeti, Steven , Kantarci, Kejal, Keene, Dirk, Knoefel, Janice E. , Lin, Weili, Masurkar, Arjun V. , Morhardt, Darby, Okonkwo, Ozioma C. , Rabinovici, Gil D. , Rahman‐Filipiak, Annalise , Reiman, Eric M., Risacher, Shannon L. , Rosen, Howie, Schneider, Lon S. , Song, Allen W. , Swerdlow, Russell H. , Vaillancourt, David E. , Villemagne, Victor L. , Qiu, Deqiang , Foroud, Tatiana, Mormino, Elizabeth C. , Kantarci, Kejal , Oomens, Julie E , Kantarci, Kejal , Rabinovici, Gil D , Dage, Jeffrey L , Cohen, Annie , Benzinger, Tammie L.S. , Burns, Jeffrey M. , Chin, Nathaniel A. , Dickerson, Bradford Clark , Donohue, Michael , Fan, Audrey Peiwen , Habes, Mohamad , Harrison, Theresa M. , Hohman, Timothy J. , Jicha, Gregory A. , Kukull, Walter A. , Lin, Weili , Lao, Patrick , Lepping, Rebecca J. , Levendovszky, Swati Rane , McConathy, Jonathan , Mindt, Mónica Rivera , Noll, Douglas C. , Parrish, Todd B. , Reiman, Eric M. , Rudolph, Marc D. , Silbert, Lisa C. , Stark, Craig E.L. , Thompson, Paul M. , Wolk, S. J. , Johnson, Sterling C.
Alzheimer's & Dementia | November 10, 2025 | Volume: 21 | Issue: 11 | Pages: No page available
Abstract INTRODUCTION The Consortium for Clarity in Alzheimer's disease related dementias (ADRD) Research Through Imaging (CLARiTI) is a study that aims to collect standardized imaging and plasma biomarkers on 2000 Clinical Core participants enrolled across all Alzheimer's Disease Research Centers (ADRC) sites. We sought to summarize the known heterogeneity across centers regarding scientific focus and initial enrollment plans for CLARiTI. METHODS We developed and distributed a survey capturing information on the 36 CLARiTI site's theme/expertise, recruitment plans, and the intersection of CLARiTI with other ADRC imaging efforts. RESULTS Anticipated CLARiTI enrollees spanned 11 different categories of suspected etiologies underlying impairment. A wide range of risk factors were endorsed across sites regarding the enrollment of unimpaired individuals. Variability also existed regarding site‐level strategies in enrollment into CLARiTI versus other imaging efforts. DISCUSSION We anticipate that the 2000 individuals that will enroll into CLARiTI will reflect the clinical heterogeneity already in place across the ADRC network. Highlights The ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) will leverage and contribute to the existing Alzheimer's Disease Research Centers (ADRC) program by supporting standardized imaging and plasma collection across all centers. We summarize the variation in scientific focus and enrollment plans across ADRC sites participating in CLARiTI. The anticipated CLARiTI cohort will reflect the clinical heterogeneity that already exists across the ADRC network. CLARiTI will contribute to scientific goals related to the detection of multi‐etiological signatures relevant for Alzheimer's disease and related disorders (ADRDs).
A randomized trial of over‐the‐counter hearing aids for adults with cognitive decline due to Alzheimer’s Disease and related dementias
Williams, Victoria J. , McAlister, Courtney, Souza, Pamela E. , Mueller, Kimberly Diggle , Chin, Nathaniel A.
Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S8 | Pages: No page available
AbstractBackgroundHearing loss occurs commonly with age and is more prevalent among adults with Mild Cognitive Impairment (MCI) or Alzheimer’s Disease and related dementias (ADRD) than among older adults with typical cognitive abilities. Over‐the‐counter (OTC) hearing aids are a recently approved, lower‐cost method of hearing treatment which can be accessed directly by patients. However, there are almost no data which can guide whether to recommend this treatment for adults with MCI or ADRD. OTC aids also have technology constraints that may limit their benefit for wearers with ADRD, who have specific communication and rehabilitation needs.MethodParticipants in this randomized clinical trial will be recruited at the time of diagnosis of either MCI or early ADRD. The trial design embeds a brief hearing assessment within the structure of a memory assessment at Geriatrics and Neurology clinics, in both urban (Madison, WI) and rural (La Crosse, WI) settings. Trial participants will be randomized to receive either OTC aids or communication strategies tailored for adults with cognitive decline. To maximize access for patients (including patients from rural or underserved areas), treatment will be delivered via telehealth. Outcomes will be measured at baseline and after one month of use of the OTC hearing aids or communication strategies. The primary outcome is subjective assessment of dyadic communication by the listener’s primary communication partner. Additional outcomes include hearing‐related quality of life and a novel assessment of communication ability using structured conversation analysis.ResultThis presentation will describe the trial design, expertise and roles of the multidisciplinary study team, mechanism of treatment delivery via telehealth, and planned outcome measurements.ConclusionResults of this trial will provide important evidence to guide treatment recommendations in community‐dwelling older adults with MCI or early ADRD. This project will also establish feasibility of conducting hearing assessment as part of a memory assessment.